Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
The emergence of new infections in India is a growing concern
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Subscribe To Our Newsletter & Stay Updated
